Your browser doesn't support javascript.
loading
Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity.
Rössler, Annika; Kimpel, Janine; Fleischer, Verena; Huber, Silke; von Laer, Dorothee; Borena, Wegene; Würzner, Reinhard.
Afiliação
  • Rössler A; Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
  • Kimpel J; Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
  • Fleischer V; Institute of Hygiene and Medical Microbiology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
  • Huber S; Institute of Hygiene and Medical Microbiology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
  • von Laer D; Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
  • Borena W; Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
  • Würzner R; Institute of Hygiene and Medical Microbiology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
J Infect Dis ; 226(11): 1909-1912, 2022 11 28.
Article em En | MEDLINE | ID: mdl-36111560
ABSTRACT
We investigated antibody titers and avidity after heterologous versus homologous coronavirus disease 2019 vaccination over 6 months after the second dose. We found a significantly higher avidity in regimens including at least 1 dose of the adenoviral vector vaccine ChAdOx1-S compared with 2 doses of the mRNA vaccine BNT162b2.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Vacina BNT162 / ChAdOx1 nCoV-19 / Afinidade de Anticorpos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Vacina BNT162 / ChAdOx1 nCoV-19 / Afinidade de Anticorpos Idioma: En Ano de publicação: 2022 Tipo de documento: Article